Untitled design

Volition presents at EuroMedLab 2022

April 08, 2022


There are over 544,000 new cases of Non-Hodgkin lymphoma (NHLym) diagnosed worldwide each year and approximately 260,000 deaths. The non-specific symptoms of lymphoma often delay diagnosis. Alterations of epigenetic modifications have been demonstrated as an important player in human cancer including lymphoma. However, the epigenetic profile of histone post-translational modifications (PTMs) on circulating nucleosomes is still not well described.

We have developed a fast and robust enrichment method to isolate circulating nucleosomes from plasma for further downstream proteomic analysis (Nu.Q®-MS). We implemented this innovative method in a pilot study composed by plasma samples from NHLym cancer patients (n=9) and healthy controls (n=6). By comparing NHLym vs healthy plasma samples after Nu.Q® Capture-MS protocol, we identified 56 histone proteoforms. Core histone proteins such as histone H3 and H4 were identified in all immunoprecipitated samples confirming the immunoprecipitation of circulating nucleosomes. Among the histone peptides identified, we found 5 histone PTMs, located at 5 different sites, differentially represented in plasma from NHLym patients or healthy donors (p < 0.05). Altogether these data suggest that the Nu.Q® Capture protocol is effective to isolate circulating nucleosomes from plasma samples of NHLym patients to allow their subsequent analysis by mass spectrometry and the discovery of potential biomarkers for NHLym cancer diagnosis

For more information:

You can download our EuroMedLab poster here in our scientific clinical papers and posters section, which has a range of resources you can use to learn more about the science of what we do here at Volition.

EuroMedLab 2022 takes place at the ICM – Internationales Congress Center München, from Monday 11th April 2022, you can find out more details about this event here.